Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Regeneron Pharmaceuticals entered into a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis’ Helicon peptide platform. The partnership will focus on creating Helicons (stabilized, cell-penetrant alpha-helical peptides) that can be used as standalone therapies or as components of antibody-Helicon conjugates/AHCs to reach previously “undruggable” intracellular protein targets.

Under the agreement, Parabilis will receive $125 million, consisting of a $50 million upfront payment and a $75 million investment from Regeneron in future equity financing. Parabilis is also eligible for up to $2.2 billion in milestone payments and tiered royalties. The companies will jointly discover new therapeutic candidates, while Regeneron will manage subsequent development, manufacturing, and global commercialization.

This collaboration aims to combine Regeneron’s antibody expertise with Parabilis’ peptide technology to create a new class of therapeutics. This deal follows another significant investment by Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) last month, when the company partnered with Telix Pharmaceuticals in a deal worth up to $4.3 billion to develop new radiopharmaceutical therapies.

Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target 'Undruggable' Proteins

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a biotechnology firm. It works in the discovery, invention, development, manufacturing, and marketing of pharmaceuticals. Its brand lineup includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1